squattie

CELH to the moon

squattie Updated   
NASDAQ:CELH   Celsius Holdings, Inc.
Look at text
Comment:
Base 1 2 3 4 5 6 7 8 9 10 Terminal Year
Revenue Growth Rate 42.00% 41.00% 40.00% 38.00% 36.00% 34.00% 32.00% 30.00% 20.00% 20.00% 5%
Revenues $88,846,000 $126,161,320 $177,887,461 $249,042,446 $343,678,575 $467,402,862 $626,319,835 $826,742,182 $1,074,764,837 $1,289,717,805 $1,547,661,365 $1,625,044,434
Operating Margin 0.25% 11.01% 17.09% 20.53% 22.47% 23.57% 24.19% 24.54% 24.74% 24.85% 24.92% 25.00%
EBIT $218,246 $13,888,353 $30,404,007 $51,128,654 $77,236,717 $110,176,188 $151,524,729 $202,913,905 $265,919,873 $320,549,762 $385,640,422 $406,261,108
Taxes $0 $0 $0 $8,139,504 $19,309,179 $27,544,047 $37,881,182 $50,728,476 $66,479,968 $80,137,441 $96,410,106 $101,565,277
EBIT(1-t) $218,246 $13,888,353 $30,404,007 $42,989,151 $57,927,538 $82,632,141 $113,643,547 $152,185,429 $199,439,905 $240,412,322 $289,230,317 $304,695,831
+ Depreciation $143,528 $198,069 $269,373 $360,960 $476,468 $619,408 $743,289 $891,947 $936,545 $983,372 $1,032,541 $1,084,168
- Capital Expenditures $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $0 $54,763,717
- Chg WC $6,600,000 $3,500,700 $4,852,637 $6,675,335 $8,878,195 $11,607,072 $14,908,639 $18,802,425 $23,268,001 $20,165,601 $24,198,721 $7,259,616
FCFF -$6,238,226 $10,585,722 $25,820,744 $36,674,776 $49,525,810 $71,644,476 $99,478,197 $134,274,951 $177,108,449 $221,230,093 $266,064,136 $243,756,665
NOL $62,863,000 $48,974,647 $18,570,639 $0 $0 $0 $0 $0 $0 $0 $0 $0
Terminal Value $3,994,046,617
Comment:
This assumes a market risk premium of 6.5% and terminal growth rate of 32.1%. It should be noted during Monster's 44% CAGR period between 2012 and 2014, stock price appreciated from $6 to a blow of top of $28 roughly 18 months later. Celsius is showing similar sales velocity during cost consolidation and DSD transitions. Low side target of $19.71 and high side of $26.42, largely dependent on market risk premium of 6.5% and 5.5%, respectively.
Comment:
Almost perfect valuation at the top!
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.